- Home
- GLUE vs AVTX Comparison
GLUE vs AVTX Comparison
Compare GLUE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | AVTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 248.3M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GLUE | AVTX |
|---|---|---|
| Price | $16.23 | $19.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $15.00 | ★ $30.14 |
| AVG Volume (30 Days) | ★ 980.7K | 357.4K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $181,538,000.00 | $192,000.00 |
| Revenue This Year | $66.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.10 | ★ N/A |
| Revenue Growth | ★ 1112.27 | N/A |
| 52 Week Low | $3.50 | $3.39 |
| 52 Week High | $16.66 | $19.41 |
Technical Indicators
Market Signals| Indicator | GLUE | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.97 | 65.82 |
| Support Level | $13.27 | $16.75 |
| Resistance Level | $16.66 | $19.29 |
| Average True Range (ATR) | 1.02 | 1.37 |
| MACD | 0.08 | 0.18 |
| Stochastic Oscillator | 88.50 | 95.27 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).